A Phase 1, Open-Label, Single Dose, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Desidustat for Treatment of Anemia in Patients Receiving Chemotherapy
Latest Information Update: 05 Oct 2022
At a glance
- Drugs Desidustat (Primary)
- Indications Chemotherapy-induced anaemia
- Focus Adverse reactions
- Sponsors Zydus Lifesciences
- 17 May 2022 Status changed from recruiting to completed.
- 11 Dec 2020 Status changed from active, no longer recruiting to recruiting.
- 08 Dec 2020 Status changed from planning to active, no longer recruiting.